MTFL457 peptide protects against cochlear synaptopathy and noise-induced hearing loss by preventing TrkB-FL degradation
Background
Noise-induced hearing loss (NIHL) is the second leading cause of global deafness, yet effective pharmacological treatments remain elusive. A central mechanism in early NIHL is excitotoxicity, leading to degeneration of cochlear synapses between inner hair cells (IHCs) and spiral ganglion neurons (SGNs). This damage can trigger degradation of the neurotrophic TrkB receptor, inhibiting BDNF signaling and complicating neurotrophin-based therapies. Addressing this TrkB degradation is a critical therapeutic gap.
Study Design
Researchers investigated MTFL457, a cell-penetrating peptide designed to prevent TrkB-FL degradation, in models of cochlear damage. An ex vivo model induced excitotoxicity in cochlear explants via glutamate receptor overstimulation. An in vivo model involved noise overexposure in mice. Effects on the neurotrophic system and cell architecture were assessed by immunohistochemistry. Hearing function in vivo was evaluated using the auditory brainstem responses (ABR) test, performed before and after noise exposure, comparing treated groups to controls.
Results
MTFL457 demonstrated efficient distribution across cochlear cell types in both ex vivo and in vivo models, suggesting its ability to reach the inner ear and potentially cross the blood-labyrinth barrier after systemic administration. In explants undergoing excitotoxicity, MTFL457 prevented TrkB-FL dysregulation, partially restored downstream prosurvival signaling, and significantly reduced neuronal damage and features associated with cochlear synaptopathy. In vivo, despite known sex-dependent differences in susceptibility to noise-induced damage, treatment with MTFL457 preserved auditory function and synaptic integrity in both males and females, though the magnitude of protection varied. These findings collectively support a protective effect of MTFL457.
MTFL457 prevented
TrkB-FLdysregulation, partially restored downstream prosurvival signaling, and significantly reduced neuronal damage in excitotoxicity-induced cochlear explants.
Key Findings
- MTFL457 efficiently distributed across cochlear cell types in ex vivo and in vivo models.
- MTFL457 prevented
TrkB-FLdysregulation in excitotoxicity-induced cochlear explants. - MTFL457 partially restored prosurvival signaling and significantly reduced neuronal damage ex vivo.
- MTFL457 preserved auditory function and synaptic integrity in vivo in both male and female mice.
Why It Matters
MTFL457 offers a promising neuroprotective strategy for noise-induced hearing loss by directly targeting TrkB-FL degradation, a key mechanism in cochlear synaptopathy. This approach could circumvent limitations of traditional neurotrophin therapies by stabilizing the receptor itself. While preclinical, the peptide's efficient distribution and ability to cross the blood-labyrinth barrier suggest potential for systemic administration, simplifying future clinical translation. This opens a new avenue for pharmacological intervention in NIHL, moving beyond current symptomatic treatments to address underlying neuronal damage.
mtfl457
noise-induced-hearing-loss
cochlear-synaptopathy
trkb
neuroprotection
excitotoxicity